Report Highlights

The United States' Role in the Global Food Enzymes Supply Chain

The United States sits at the centre of global food enzyme production, combining domestic fermentation capacity with large-scale downstream demand. Novonesis operates its principal North American fermentation complex in Franklinton, North Carolina, supplying amylase, protease and lactase grades to bakeries, brewers and dairy processors nationwide. Corn wet-milling output from Cargill, ADM and Ingredion in the Midwest supplies glucose and dextrose substrate, making the Corn Belt the cost anchor for domestic enzyme production.

Import dependency is concentrated in specialty grades rather than bulk volumes. Denmark, the Netherlands and Japan supply high-purity lactase, phytase and transglutaminase, with Danish shipments routed through the Port of New York and New Jersey on ocean carriers. Mexico and Canada receive U.S.-formulated blends under USMCA, and the country adds value through formulation, encapsulation and blending operations in Illinois, New Jersey and Ohio before re-export.

Growth Drivers for U.S. Food Enzymes Trade and Production

Clean-label reformulation is the first driver. Manufacturers replacing chemical processing aids are specifying enzymes, lifting demand for lactase in lactose-free dairy and transglutaminase in plant-based protein. Dairy processors in Wisconsin and California and plant-protein producers in Texas are converting legacy lines, creating multi-year procurement contracts with domestic enzyme suppliers.

Biomanufacturing reshoring is the second driver. Capacity expansions by Novonesis and IFF, supported by federal biomanufacturing incentives, are reducing reliance on China-origin phytase. Enzymes used in corn starch processing for food sweeteners share the same Midwest supply base, which gives producers scale economies across food and industrial output.

Supply Chain Risks and Trade Barriers

Feedstock volatility is the most immediate risk. Corn price swings directly alter the cost of glucose and dextrose substrate, compressing margins for fermentation plants in Iowa and Illinois. Tariffs under Section 301 on Chinese-origin inputs raise landed costs for importers, while Gulf port congestion at New Orleans and Houston lengthens transit times for liquid enzyme shipments that require temperature-controlled handling.

Regulatory and currency exposure compounds these pressures. FDA scrutiny of the self-affirmed GRAS pathway raises the cost and timeline of bringing new enzyme preparations to market. Danish imports priced in euros expose U.S. buyers to EUR/USD swings, and a strengthening dollar would narrow the gap between domestic and imported specialty grades.

Trade and Investment Opportunities in the United States

Import substitution in phytase represents the clearest near-term opportunity. Replacing China-origin supply with domestically fermented product from Franklinton and contract manufacturers in the Midwest would cut tariff exposure and shorten lead times. Mexican food processors served through Laredo rail corridors also present an export channel for U.S.-formulated enzyme blends under USMCA rules of origin.

Logistics hub development offers the second opportunity. Memphis, with its established cold-chain distribution infrastructure, is positioned as a distribution node for liquid enzymes moving to Southeastern processors. Inbound foreign direct investment in fermentation capacity across Indiana and Ohio, close to corn feedstock and interstate rail, would strengthen domestic supply resilience.

Market at a Glance

Leading Market Participants

• Novonesis
• IFF
• dsm-firmenich
• AB Enzymes
• Amano Enzyme
• Kerry Group
• BASF
• Advanced Enzyme Technologies
• Biocatalysts
• Dyadic International

Regulatory and Trade Policy Environment

The FDA regulates food enzymes through its GRAS notification program and food additive petition process under the Federal Food, Drug, and Cosmetic Act. Enzyme products are classified under HTS heading 3507, which determines duty treatment on imports. Section 301 tariffs apply to Chinese-origin products, and USMCA rules of origin govern duty-free access for enzyme blends traded with Mexico and Canada.

Investment and procurement policy adds a second layer. CFIUS reviews foreign acquisitions of domestic fermentation assets, shaping ownership of plants in the Midwest. USDA BioPreferred certification and Buy American requirements favour domestically produced enzymes in federal food procurement, while state incentives in Iowa and Indiana support new fermentation capacity.

U.S. Food Enzymes Supply Chain Outlook to 2032

Domestic production will absorb a growing share of specialty demand through 2032 as Franklinton and Midwest contract plants add lactase and phytase lines. Trade flows will shift from Danish-origin imports toward U.S. output, with Mexico and Canada becoming a larger share of exports. Cost curves will tighten as corn substrate supply stays anchored in the Corn Belt.

Technology will reshape comparative advantage over the forecast period. AI-guided enzyme engineering and precision fermentation reduce dependence on imported specialty strains, favouring firms with established U.S. R&D and fermentation infrastructure. Producers that integrate these platforms with Midwest feedstock supply will hold the strongest position in the domestic supply chain.